Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90


Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.

Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A.

Radiother Oncol. 2019 Jun 29;140:105-109. doi: 10.1016/j.radonc.2019.06.018. [Epub ahead of print]


A priori prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks.

Tadayyon H, Gangeh M, Sannachi L, Trudeau M, Pritchard K, Ghandi S, Eisen A, Look-Hong N, Holloway C, Wright F, Rakovitch E, Vesprini D, Tran WT, Curpen B, Czarnota G.

Oncotarget. 2019 Jun 11;10(39):3910-3923. doi: 10.18632/oncotarget.26996. eCollection 2019 Jun 11.


Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.

Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, Bristow RG, Downes M, Vesprini D, Liu S, Bapat B, Boutros PC.

J Natl Cancer Inst. 2019 Jun 4. pii: djz112. doi: 10.1093/jnci/djz112. [Epub ahead of print]


Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.

Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC.

Clin Oncol (R Coll Radiol). 2019 May 21. pii: S0936-6555(19)30193-1. doi: 10.1016/j.clon.2019.05.001. [Epub ahead of print]


Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.

Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK.

J Transl Med. 2019 May 23;17(1):173. doi: 10.1186/s12967-019-1920-5.


Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer.

Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G.

Radiother Oncol. 2019 Jun;135:170-177. doi: 10.1016/j.radonc.2019.03.007. Epub 2019 Mar 27.


Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study.

Alayed Y, Loblaw A, Chu W, Al-Hanaqta M, Chiang A, Jain S, Chung H, Vesprini D, Morton G, Ravi A, Davidson M, Deabreu A, Mamedov A, Zhang L, Erler D, Cheung P.

Int J Radiat Oncol Biol Phys. 2019 Apr 16. pii: S0360-3016(19)30624-8. doi: 10.1016/j.ijrobp.2019.04.006. [Epub ahead of print]


Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.

Klein J, Tran W, Watkins E, Vesprini D, Wright FC, Look Hong NJ, Ghandi S, Kiss A, Czarnota GJ.

BMC Cancer. 2019 Apr 3;19(1):306. doi: 10.1186/s12885-019-5499-2.


Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.

Zhao F, Vesprini D, Liu RSC, Olkhov-Mitsel E, Klotz LH, Loblaw A, Liu SK, Bapat B.

Urol Oncol. 2019 May;37(5):297.e9-297.e17. doi: 10.1016/j.urolonc.2019.01.031. Epub 2019 Feb 16.


Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Apr;201(4):721-727. doi: 10.1097/JU.0000000000000031.


SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.

Alayed Y, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Musunuru HB, Davidson M, Ravi A, Ho L, Deabreu A, D'Alimonte L, Bhounr Z, Zhang L, Commisso K, Loblaw A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):36-41. doi: 10.1016/j.ijrobp.2018.11.011. Epub 2018 Nov 14.


Palliative treatment of metastatic phyllodes tumors: a case series.

Ganesh V, Lee J, Wan BA, Rakovitch E, Vesprini D, Slodkowska E, Zeng KL, Sousa P, Yee C, Chow E.

AME Case Rep. 2017 Dec 21;1:9. doi: 10.21037/acr.2017.12.01. eCollection 2017.


Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.

Hahn E, Liu SK, Vesprini D, Xu B, Downes MR.

J Clin Pathol. 2018 Nov;71(11):1023-1027. doi: 10.1136/jclinpath-2018-205404. Epub 2018 Sep 26.


Response to: The Survival Time of 8376 Male Breast Cancer Patients.

Wan BA, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, Vesprini D, Lee J, Rakovitch E, Lu FI, Eisen A, Yee C, Lam H, Chow E.

Clin Oncol (R Coll Radiol). 2018 Dec;30(12):818-819. doi: 10.1016/j.clon.2018.08.011. Epub 2018 Sep 10. No abstract available.


Radiotherapy for patients with unresected locally advanced breast cancer.

Yee C, Alayed Y, Drost L, Karam I, Vesprini D, McCann C, Soliman H, Zhang L, Chow E, Chan S, Lee J.

Ann Palliat Med. 2018 Oct;7(4):373-384. doi: 10.21037/apm.2018.05.13. Epub 2018 Jun 12.


Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.

Wang C, Hahn E, Slodkowska E, Eskander A, Enepekides D, Higgins K, Vesprini D, Liu SK, Downes MR, Xu B.

Hum Pathol. 2018 Dec;82:131-139. doi: 10.1016/j.humpath.2018.07.024. Epub 2018 Aug 1.


Radiation-induced Skin Toxicity in Breast Cancer Patients: A Systematic Review of Randomized Trials.

Yee C, Wang K, Asthana R, Drost L, Lam H, Lee J, Vesprini D, Leung E, DeAngelis C, Chow E.

Clin Breast Cancer. 2018 Oct;18(5):e825-e840. doi: 10.1016/j.clbc.2018.06.015. Epub 2018 Jul 4. Review.


Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.

Musunuru HB, D'Alimonte L, Davidson M, Ho L, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Ravi A, Deabreu A, Zhang L, Commisso K, Loblaw A.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1438-1447. doi: 10.1016/j.ijrobp.2018.07.2005. Epub 2018 Jul 31.


Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.

Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin J, Pond GR, Haider M.

Eur Urol. 2019 Feb;75(2):300-309. doi: 10.1016/j.eururo.2018.06.025. Epub 2018 Jul 13.


A Systematic Review of Heart Dose in Breast Radiotherapy.

Drost L, Yee C, Lam H, Zhang L, Wronski M, McCann C, Lee J, Vesprini D, Leung E, Chow E.

Clin Breast Cancer. 2018 Oct;18(5):e819-e824. doi: 10.1016/j.clbc.2018.05.010. Epub 2018 Jun 14. Review.


Basal-subtype bladder tumours show a 'hot' immunophenotype.

Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR.

Histopathology. 2018 Nov;73(5):748-757. doi: 10.1111/his.13696. Epub 2018 Aug 14.


Early Local Recurrence in a Patient With Encapsulated Papillary Carcinoma of the Breast.

Yee C, Drost L, Niglas M, Chow E, Vesprini D.

Clin Breast Cancer. 2018 Aug;18(4):e447-e448. doi: 10.1016/j.clbc.2018.05.001. Epub 2018 May 9. No abstract available.


PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.

Hodgson A, Slodkowska E, Jungbluth A, Liu SK, Vesprini D, Enepekides D, Higgins K, Katabi N, Xu B, Downes MR.

Am J Surg Pathol. 2018 Aug;42(8):1059-1066. doi: 10.1097/PAS.0000000000001084.


Male Oncology Research and Education program for men at high risk for prostate cancer.

Lorentz J, Liu SK, Vesprini D.

Curr Oncol. 2018 Apr;25(2):170-175. doi: 10.3747/co.25.3818. Epub 2018 Apr 30.


Prospective Study of Breast Radiation Dermatitis.

Drost L, Li N, Vesprini D, Sangha A, Lee J, Leung E, Rakovitch E, Yee C, Chow E, Ruschin M.

Clin Breast Cancer. 2018 Oct;18(5):e789-e795. doi: 10.1016/j.clbc.2018.03.008. Epub 2018 Mar 15.


Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.

Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A.

Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15.


Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients.

Wan BA, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, Vesprini D, Lee J, Rakovitch E, Lu FI, Eisen A, Yee C, Lam H, Chow E.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):354-365. doi: 10.1016/j.clon.2018.02.026. Epub 2018 Mar 2.


"Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.

Skop M, Lorentz J, Jassi M, Vesprini D, Einstein G.

Am J Mens Health. 2018 Jul;12(4):961-972. doi: 10.1177/1557988317753241. Epub 2018 Feb 5.


Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment?

Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, van Herk M, Li XA, Mittauer K, Ritter M, Choudhury A, Tree AC.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):361-373. doi: 10.1016/j.ijrobp.2017.10.020. Epub 2017 Oct 26. Review.


To prep or not to prep - that is the question: A randomized trial on the use of antiflatulent medication as part of bowel preparation for patients having image guided external beam radiation therapy to the prostate.

McGuffin M, Devji N, Kehoe L, Carty A, Russell S, Di Prospero L, DeAngelis C, Kiss A, Vesprini D, Loblaw A, D'Alimonte L.

Pract Radiat Oncol. 2018 Mar - Apr;8(2):116-122. doi: 10.1016/j.prro.2017.10.012. Epub 2017 Nov 4.


Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.

Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE, Bapat B.

J Urol. 2018 Jun;199(6):1475-1481. doi: 10.1016/j.juro.2017.12.006. Epub 2017 Dec 12.


A retrospective review of phyllodes tumours of the breast: A single institution experience.

Ganesh V, Drost L, Lee J, Wan BA, Zhang L, Rakovitch E, Vesprini D, Slodkowska E, Zeng KL, Sousa P, Yee C, Lam H, Chow E.

Breast. 2018 Apr;38:52-57. doi: 10.1016/j.breast.2017.12.008. Epub 2017 Dec 9.


Patient-Reported Outcomes following Breast Conservation Therapy and Barriers to Referral for Partial Breast Reconstruction.

Vrouwe SQ, Somogyi RB, Snell L, McMillan C, Vesprini D, Lipa JE.

Plast Reconstr Surg. 2018 Jan;141(1):1-9. doi: 10.1097/PRS.0000000000003914.


Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.

Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, Chung HT, D'Alimonte L, Krahn M, Morton G, Loblaw A.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):718-731. doi: 10.1016/j.clon.2017.08.002. Epub 2017 Sep 12.


Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer.

Ghiam AF, Vesprini D, Liu SK.

Transl Androl Urol. 2017 Apr;6(2):326-330. doi: 10.21037/tau.2017.03.06.


Improving prostate cancer care collaboratively - a multidisciplinary, formal, consensus-based approach.

Loblaw A, Barkin J, Buckley R, Chung H, Kell J, Singal R, Spodek J, Vesprini D, Flax S.

Can J Urol. 2017 Feb;24(1):8646-8650.


Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer.

Fotouhi Ghiam A, Taeb S, Huang X, Huang V, Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, Bristow RG, Vesprini D, Boutros P, Liu SK.

Oncotarget. 2017 Jan 17;8(3):4668-4689. doi: 10.18632/oncotarget.13576.


Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B.

J Urol. 2017 Feb;197(2):335-341. doi: 10.1016/j.juro.2016.08.081. Epub 2016 Aug 18.


Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.

J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26.


Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).

Dawdy K, Bonin K, Russell S, Ryzynski A, Harth T, Townsend C, Liu S, Chu W, Cheung P, Chung H, Morton G, Vesprini D, Loblaw A, Cao X, Szumacher E.

J Cancer Educ. 2018 Jun;33(3):551-556. doi: 10.1007/s13187-016-1091-5.


Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC).

Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18.


MRI-guided prostate adaptive radiotherapy - A systematic review.

McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A; MR-Linac consortium.

Radiother Oncol. 2016 Jun;119(3):371-80. doi: 10.1016/j.radonc.2016.04.014. Epub 2016 May 6. Review.


Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

Musunuru HB, Davidson M, Cheung P, Vesprini D, Liu S, Chung H, Chu W, Mamedov A, Ravi A, D'Alimonte L, Commisso K, Helou J, Deabreu A, Zhang L, Loblaw A.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1043-51. doi: 10.1016/j.ijrobp.2015.12.010. Epub 2015 Dec 23.


Breast Cancer Patients' Preferences for Adjuvant Radiotherapy Post Lumpectomy: Whole Breast Irradiation vs. Partial Breast Irradiation-Single Institutional Study.

Bonin K, McGuffin M, Presutti R, Harth T, Mesci A, Feldman-Stewart D, Chow E, Di Prospero L, Vesprini D, Rakovitch E, Lee J, Paszat L, Doherty M, Soliman H, Ackerman I, Cao X, Kiss A, Szumacher E.

J Cancer Educ. 2018 Feb;33(1):37-43. doi: 10.1007/s13187-016-1016-3.


A dosimetric study of cardiac dose sparing using the reverse semi-decubitus technique for left breast and internal mammary chain irradiation.

Niglas M, McCann C, Keller BM, Makhani N, Presutti J, Vesprini D, Rakovitch E, Elzibak A, Mashouf S, Lee J.

Radiother Oncol. 2016 Jan;118(1):187-93. doi: 10.1016/j.radonc.2015.12.013. Epub 2016 Jan 12.


Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.

Yamamoto T, Musunuru HB, Vesprini D, Zhang L, Ghanem G, Loblaw A, Klotz L.

J Urol. 2016 May;195(5):1409-1414. doi: 10.1016/j.juro.2015.11.075. Epub 2015 Dec 18.


Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.

Jain S, Loblaw A, Vesprini D, Zhang L, Kattan MW, Mamedov A, Jethava V, Sethukavalan P, Yu C, Klotz L.

J Urol. 2015 Jul;194(1):79-84. doi: 10.1016/j.juro.2015.01.102. Epub 2015 Feb 4.


MicroRNA in radiotherapy: miRage or miRador?

Korpela E, Vesprini D, Liu SK.

Br J Cancer. 2015 Mar 3;112(5):777-82. doi: 10.1038/bjc.2015.6. Epub 2015 Jan 22. Review.


Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A.

J Clin Oncol. 2015 Jan 20;33(3):272-7. doi: 10.1200/JCO.2014.55.1192. Epub 2014 Dec 15.


Supplemental Content

Loading ...
Support Center